Pulmonary alveolar proteinosis
surfactant accumulation · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Pulmonary alveolar proteinosis is accumulation of surfactant-derived material in alveoli, most commonly autoimmune (anti-GM-CSF antibodies). It causes progressive breathlessness and hypoxaemia with a characteristic crazy-paving CT pattern; whole-lung lavage is the mainstay treatment.
Red flags
- Severe refractory hypoxaemia
- Superimposed opportunistic infection
- Rapid deterioration
- Secondary PAP from undiagnosed haematological malignancy
Assessment
Differential diagnosis
- Pneumocystis jirovecii pneumonia
- Pulmonary oedema
- Lipoid pneumonia
- Organising pneumonia
- Diffuse alveolar haemorrhage
- Hypersensitivity pneumonitis
Investigations
- HRCT chest (crazy-paving: ground glass with interlobular septal thickening)
- Serum anti-GM-CSF antibody (diagnostic of autoimmune PAP)
- BAL showing milky, PAS-positive proteinaceous material
- Lung function (restriction, low DLCO) and resting/exertional oximetry
- Exclude secondary causes (haematological disease, dust exposure, infection)
Management
- Suspect in progressive dyspnoea with crazy-paving on CT disproportionate to symptoms
- Confirm with serum anti-GM-CSF antibody and characteristic BAL findings
- Classify as autoimmune, secondary or congenital
- Assess severity with oxygenation and lung function
- Observe mild/asymptomatic disease as some stabilise spontaneously
- Perform whole-lung lavage for significant hypoxaemia or functional impairment
- Consider inhaled/subcutaneous GM-CSF therapy in autoimmune disease
- Treat secondary PAP by addressing the underlying condition
- Monitor for superimposed opportunistic infection (nocardia, mycobacteria, fungi)
- Follow up with serial imaging, physiology and lavage as needed
Drugs & doses
Inhaled GM-CSF (e.g. sargramostim/molgramostim) for autoimmune PAP
Supplemental oxygen as required
Treat secondary infection with pathogen-directed antimicrobials
Rituximab or plasmapheresis in refractory autoimmune disease (selected centres)
Disposition
Specialist / national PAP centre for whole-lung lavage and GM-CSF therapy; monitor for infection.
Complications & pitfalls
- Respiratory failure
- Secondary opportunistic infection (especially Nocardia)
- Pulmonary fibrosis in chronic disease
- Recurrence requiring repeated lavage
Exam pearls
- Crazy-paving with disproportionately mild symptoms should prompt consideration of PAP
- Anti-GM-CSF antibody confirms the common autoimmune form non-invasively
- Whole-lung lavage remains the mainstay for symptomatic disease
- Be alert for opportunistic infection, particularly Nocardia
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.